BCR/ABL Minor Quantitative Test
Cost: AED 2040.0
Test Details
The BCR/ABL minor quantitative test is a laboratory test used to monitor the levels of BCR/ABL fusion gene transcripts in patients with chronic myeloid leukemia (CML). CML is a type of cancer that affects the bone marrow and results in the overproduction of white blood cells.
The majority of CML cases are caused by a genetic abnormality known as the Philadelphia chromosome, which results in the fusion of the BCR and ABL genes. This fusion gene, known as BCR/ABL, produces a protein that promotes the uncontrolled growth of white blood cells.
The BCR/ABL minor quantitative test is performed using a technique called polymerase chain reaction (PCR). It measures the amount of BCR/ABL fusion gene transcripts in a patient’s blood or bone marrow sample. The test provides a quantitative result, indicating the number of BCR/ABL transcripts per a standardized amount of RNA.
Monitoring the levels of BCR/ABL fusion gene transcripts is important in the management of CML. The test can be used to assess the response to treatment and detect early signs of disease relapse. A decrease in BCR/ABL transcript levels indicates a good response to treatment, while an increase may indicate disease progression or resistance to therapy.
The BCR/ABL minor quantitative test is typically performed at regular intervals during the course of CML treatment. The results are interpreted in conjunction with other clinical and laboratory findings to guide treatment decisions.
Test Components
- Price: AED 2040.0
- Sample Condition: Whole Blood, Culture Cells, Bone marrow aspirations
- Report Delivery: 3rd Working Day Email – 36 hours, On phone – 24 hours
- Method: Real Time PCR
- Test type: Viral
- Doctor: Physician
- Test Department: Genetics
Pre Test Information
Before undergoing the BCR/ABL minor quantitative test, patients need to sign a consent document and bring any clinical history of the patient for the test.
| Test Name | BCRABL Minor Quantitative Test |
|---|---|
| Components | |
| Price | 2040.0 AED |
| Sample Condition | Whole Blood, Culture Cells, Bone marrow aspirations, |
| Report Delivery | 3rd Working Day Email:-36 hours. On phone: 24 hours |
| Method | Real Time PCR |
| Test type | Viral |
| Doctor | Physician |
| Test Department: | Genetics |
| Pre Test Information | Need to sign Consent document and bring any clinical history of patient forBCR/ABL Minor QuantitativeTest |
| Test Details |
The BCR/ABL minor quantitative test is a laboratory test used to monitor the levels of BCR/ABL fusion gene transcripts in patients with chronic myeloid leukemia (CML). CML is a type of cancer that affects the bone marrow and results in the overproduction of white blood cells. The majority of CML cases are caused by a genetic abnormality known as the Philadelphia chromosome, which results in the fusion of the BCR and ABL genes. This fusion gene, known as BCR/ABL, produces a protein that promotes the uncontrolled growth of white blood cells. The BCR/ABL minor quantitative test is performed using a technique called polymerase chain reaction (PCR). It measures the amount of BCR/ABL fusion gene transcripts in a patient’s blood or bone marrow sample. The test provides a quantitative result, indicating the number of BCR/ABL transcripts per a standardized amount of RNA. Monitoring the levels of BCR/ABL fusion gene transcripts is important in the management of CML. The test can be used to assess the response to treatment and detect early signs of disease relapse. A decrease in BCR/ABL transcript levels indicates a good response to treatment, while an increase may indicate disease progression or resistance to therapy. The BCR/ABL minor quantitative test is typically performed at regular intervals during the course of CML treatment. The results are interpreted in conjunction with other clinical and laboratory findings to guide treatment decisions. |
